Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Significant ADHD symptom control with shorter Daytrana wear time

May 30, 2006

Case Western to study rEV-576 for myasthenia gravis

May 30, 2006

Enrollment completed in first phase III trial of PRX-00023 in GAD

May 30, 2006

Cannabinoid CB2 receptors as a target for anxiety and substance abuse

May 29, 2006

Recent patents describe novel agents for anxiety, depression, psychosis, etc.

May 29, 2006

EnVivo sets out plans for drug development progression

May 29, 2006

Pagoclone produces decrease in severity of stuttering

May 29, 2006

URB-597 has antidepressant activity in animal models

May 29, 2006

Quetiapine shows potential as monotherapy in bipolar depression

May 26, 2006

Three new mechanism-of-action studies begin for VNS Therapy

May 26, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...